5-ASA 化合物在炎症性肠病中的临床药理学。
Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease.
机构信息
University of Pennsylvania School of Medicine, Suite 100, Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104, USA.
出版信息
Gastroenterol Clin North Am. 2010 Sep;39(3):559-99. doi: 10.1016/j.gtc.2010.08.011.
PMID:20951918
Abstract
Mesalamine has been the first-line of therapy in patients with inflammatory bowel disease (IBD) since the 1960s. This article serves as a review of the different 5-aminosalicylic acid compounds, release formulations, use and dosing in the treatment of IBD, in particular ulcerative colitis.
摘要
美沙拉嗪自 20 世纪 60 年代以来一直是炎症性肠病（IBD）患者的一线治疗药物。本文旨在回顾不同的 5-氨基水杨酸化合物、释放制剂、在治疗 IBD（尤其是溃疡性结肠炎）中的用途和剂量。
Zotero 插件